MabVax Therapeutics, Inc.

05/21/2018

MabVax is dedicated to developing novel therapeutic and diagnostic products to address unmet medical needs in the treatment of cancer. Learn more about our work on our website.

MabVax is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer.

05/17/2018

MabVax has received a U.S. patent for fully human antibodies targeting the antigen GD2 which is expressed on sarcoma, melanoma, and neuroblastoma. This is the second patent issued in the antibody portfolio created through MabVax’s unique discovery platform. Similar to the Company’s sialyl lewis A (sLea) and Thomsen-nouveau (Tn) antigen targeting antibodies, the ganglioside GD2 targeting antibodies have the potential to be developed as therapeutic and diagnostic products. “The issuance of this patent represents another valuable intellectual property asset brought forward by MabVax and is an important component of our unique discovery strategy and expands our robust patent estate. Importantly, this filing is timely as we evaluate additional product candidates that have the potential to address significant unmet needs in the treatment of cancers to fuel our pipeline and expand our partnering discussions,” stated David Hansen, MabVax's President and CEO.

Download as PDF May 17, 2018 - Company expands intellectual property estate with granted patent on antibodies that have been evaluated in preclinical studies as both a therapeutic product and a diagnostic agent SAN DIEGO, May 17, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX)...

05/16/2018

Pancreatic cancer is one of the deadliest cancers with a 5-year survival rate of only 8.5%. Cancer research is crucial for the development of novel treatments that can help improve patient outcomes. Learn more about pancreatic cancer during National Cancer Research Month.

05/15/2018

MabVax's immunoPET imaging diagnostic product, MVT-2163, has the potential to pinpoint pancreatic cancer metastatic sites and help surgeons to successfully remove the cancer.

05/11/2018

MabVax's MVT-1075 is a HuMab-5B1 antibody based radioimmunotherapy product. Learn more about the results from the initial cohort of our Phase 1 clinical study for the treatment of pancreatic, colon and lung cancer.

05/09/2018

The target of our HuMab-5B1 antibody is highly expressed in pancreatic cancer with 9 out of 10 patients having pancreatic cancer that expresses this antigen. Visit our website to learn more about our development of HuMab-5B1 based therapies and PET imaging diagnostic products. http://bit.ly/2F4Uo5b

05/08/2018

In 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States. Cancer research is vital to helping those whose lives have been affected by this global health challenge.

Basic information about cancer statistics in the U.S. and how they are used to understand the impact of cancer on society and to develop strategies that address the challenges that cancer poses.

05/07/2018

MabVax's May 3rd presentation from David Hansen, MabVax's President and Chief Executive Officer, at VirtualInvestorConferences.com is now available for on-demand viewing at VirtualInvestorConferences.com. Mr. Hansen provided a corporate overview, as well as a clinical update and outlined anticipated milestones for its Phase 1 clinical programs including the MVT-5873 clinical trial in combination with a standard of care chemotherapy as a first line therapy for patients newly diagnosed with pancreatic cancer, and the MVT-1075 radioimmunotherapy clinical trial for the treatment of pancreatic, colon and lung cancers. For more information:

Download as PDF May 07, 2018 - Company invites individual and institutional investors as well as advisors to log on to VirtualInvestorConferences.com to view presentation - SAN DIEGO, May 7, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug develo...

05/03/2018

MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering

Download as PDF May 03, 2018 SAN DIEGO, May 3, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced it has entere...

05/03/2018

Today at 10:45 a.m. EDT MabVax CEO David Hansen will present live at VirtualInvestorConferences.com. For a live webcast of the event visit:

05/02/2018

May is National Cancer Research Month. Learn how you can help spread global awareness about the importance of cancer research from the American Association of Cancer Research: http://bit.ly/2JOUSKC

04/30/2018

David Hansen, MabVax's President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on May 3 at 10:45 a.m. EDT. As part of his presentation, Mr. Hansen will provide a corporate overview, as well as a clinical update and outline anticipated milestones for its Phase 1 clinical programs including the MVT-5873 clinical trial in combination with a standard of care chemotherapy as a first line therapy for patients newly diagnosed with pancreatic cancer, and the MVT-1075 radioimmunotherapy clinical trial for the treatment of pancreatic, colon and lung cancers. For details about the conference please visit.

Download as PDF April 30, 2018 - Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual event on May 3rd at 10:45 a.m. EDT - SAN DIEGO, April 30, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncol...